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THE ALBERT LASKER AWARD FOR CLINICAL MEDICAL RESEARCH
Presented to Willem J. Kolff and Belding H. Scribner
For the development of renal hemodialysis, which changed kidney failure
from a fatal to a treatable disease, prolonging the useful lives of millions of patients.
This year’s Lasker Clinical Medical Research Award honors two scientists who changed kidney failure from a
fatal to a treatable disease. By developing the artificial kidney and devising a system for repeating hemodialysis
over a period of months and even years, Willem J. Kolff and Belding H. Scribner, respectively, have prolonged the
useful lives of millions of people.
The fate of kidney patients has undergone a revolution in the last half century, due in large part to Kolff’s and
Scribner’s seminal contributions. The kidney filters metabolic byproducts from the blood, and when it fails, patients
suffer from a variety of symptoms, including weight loss, nausea and vomiting, gastrointestinal hemorrhaging, itching,
lethargy, convulsions, and coma. Without treatment, death ensues. Hemodialyzers replace the cleansing capabilities
of the kidney, and although the organ performs other physiological tasks as well, the machine’s ability to extract
impurities bestows vitality upon formerly doomed individuals.
In the late 1930s, Kolff decided to devise a contraption that would clean tainted blood from acutely ill patients,
thereby ushering them through brief periods of time in which their kidneys failed to function. Today, a variety of
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problems can temporarily disable a kidney, such as complications from antibiotic treatment, extensive muscle injury
due to trauma, or autoimmune diseases such as systemic lupus erythematosus. Under adverse conditions—the
Germans had invaded The Netherlands, where Kolff lived and worked—he plugged away, and by the mid 1940s,
he had succeeded. He developed the first clinically useful hemodialyzer, a machine that removes toxins by encouraging
them to migrate from a patient’s blood into a rinsing bath before returning the blood to the patient. With this
treatment, the death rate from acute kidney failure plummeted.
Kolff’s breakthrough was the first of two major advances that brought dramatic new hope to kidney patients.
Fifteen years later, Scribner imagined an apparatus that would extend the benefits of Kolff’s invention to patients
with chronic kidney disease. Medical conditions such as diabetes or high blood pressure can permanently incapacitate
the organ, producing so-called end-stage renal disease (ESRD). In Kolff’s procedure, surgeons inserted needles to
access arteries and veins that sent the blood to the hemodialyzer and then received it back into the body. After a
limited number of times, such operations battered the circulatory vessels so badly that they could not be reused.
Scribner concocted a U-shaped device, or shunt, that plugged into one artery and one vein and could stay there
indefinitely. Medical staff would hook it up to the machine during dialysis and then re-cap it to restore normal
blood flow through the body.
These innovations provided life support for individuals with kidney failure. Today, hemodialyzers remain the only
external life-sustaining machines that replace a failed organ. The Kolff and Scribner instruments and others derived
from them have profoundly transformed patients’ chances of surviving a range of kidney malfunctions. Before
Kolff’s invention, mortality from acute renal failure was about 75 to 90%; now it has dropped to about 20 to 50%,
depending on the nature of the underlying disease. The Scribner shunt has dramatically expanded the utility of the
hemodialyzer, bringing it to ESRD patients. More than 350,000 patients in the United States are living with ESRD,
and more than 250,000 of them are on chronic dialysis. The others, transplant recipients, flow in and out of the
dialysis pool. Worldwide, chronic hemodialysis helps or has helped more than 1.5 million individuals.
The ability to filter impurities from patients’ blood over long periods of time has spurred research into other
aspects of kidney function that must be restored in order to faithfully mimic the natural organ’s activities. Moreover,
it has permitted the kidney transplantation field to blossom, which has benefited more than 100,000 people in the
United States alone and sparked many fundamental and applied advances in the field of immunology.
Hemodialysis has become a universal standard of care for individuals with acute and chronic kidney failure.
Furthermore, it is the first and still the only method in which a machine replaces a failed internal organ. Kolff and
Scribner’s contributions have touched millions of people across the globe, and have reached far beyond the field of
kidney biology.
LIFE-SAVING CELLOPHANE—MORE THAN A SAUSAGE CASING
In 1938, recent medical school graduate Willem Kolff faced a frustrating and painful situation. At the University
of Groningen hospital in the Netherlands, he cared for a young man who was suffering from kidney disease. Kolff
watched helplessly as toxic waste buildup slowly shut down his patient’s body and eventually claimed his life.
If only Kolff could find a way to extract the poisons produced each day, he reasoned, he might be able to save
such patients. While researching the subject, he found that others had shared his vision.
In 1913, the father of U. S. pharmacology John Abel of Johns Hopkins University and his colleagues had
experimented with the concept of an artificial kidney, and had attained some success. They laced dog blood with
aspirin, and funneled it through a series of tubes made of a porous material. During its journey, it came in contact
through the molecule-sized pores with rinsing fluid that chemically resembled healthy blood. The technique drew
out the aspirin, but it was not suitable for human use. It operated inefficiently and employed an unsafe substance
from leech heads to prevent clotting.
In 1938, Dr. Kolff had a new anticoagulant at his disposal: heparin. He still needed a filtration material, however.
He settled on sausage casing, which was composed of a thin membrane called cellophane. Others researchers had
shown that if two solutions of different chemical concentrations were separated by cellophane, molecules moved from
the pool of greater concentration to that of lower concentration. In principle, Kolff could harness this phenomenon for
hemodialysis. The toxins would travel from the blood inside the cellophane tube to the rinsing fluid on the other
side. To derive the most benefit from this system, he would design a device with the largest possible amount of
cellophane surface area to maximize the interface through which the impurities could flow.
During the next several years, Kolff built four different artificial kidneys, none of which was reliable enough for
clinical use. In the meantime, war had broken out in Europe. His strongest supporter, Department of Medicine
chief Polak Daniels, who was Jewish, committed suicide as the Nazis invaded The Netherlands. A Dutch National
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Socialist took over Daniels’s post at the University of Groningen and Kolff decided to leave. He obtained a position
as an internist in the city of Kampen, and persevered in developing his artificial kidney. This quest required great
ingenuity and courage due to the extreme hardship resulting from the German occupation. The Nazis had rationed
everything and appropriated all useful materials for their war effort. Needles were scarce and rubber tubing was so
precious that Kolff used it only where he needed flexible joints; in other places, he substituted glass tubing. The
first kidneys contained aluminum strips, and when Kolff could no longer obtain the metal, he replaced it with
wooden slats. They worked fine, except when they warped. Fortunately, he had foreseen his need for large amounts
of sausage casing, and had bought plenty of that before the Germans arrived.
He devised a fifth prototype, and persuaded the managing director of a local enamel factory, Henrick Berk, to
help him construct it. In 1942, they built the first rotating drum artificial kidney. Kolff wound 100 feet of cellophane
in a spiral pattern around a large horizontal drum, which revolved in an enamel tube containing a rinsing fluid.
Gravity drew blood in the cellophane to the lowest point, and as the drum turned, the blood worked its way from
one end of the cellophane tube to the other, releasing its impurities into the surrounding fluid as it traveled.
Most physicians had little faith in Dr. Kolff’s invention. As a result, they would only refer him patients who were
comatose and close to death. Although his initial treatments didn’t produce lasting improvements, the results
encouraged him. The first 15 patients died but not from the therapy. Furthermore, Kolff could control concentrations
of urea, a key metabolic breakdown product, and some patients awoke from their comas before succumbing again
to their illness.
In September 1945, Kolff achieved his first undeniable success. Ironically, his patient was a 67-year-old woman
who had collaborated with the Nazis. He encountered considerable hostility from the local citizens for trying to
help her, but decided to proceed, remaining true to his role as a physician and desire to develop the artificial kidney.
During the treatment, she was unconscious, and, according to an editorial he wrote in 1993, “After many hours of
dialysis, I bent over her and asked if she could hear me. She slowly opened her eyes and said, ‘I’m going to divorce
my husband.’” Her kidneys began to produce urine, she broke off her marriage, and lived for another seven years.
Kolff had achieved his first victory against kidney disease.
After the war, he sent artificial kidneys to England, Canada, and the United States. By making his machines
available worldwide, he catalyzed the rapid development of hemodialysis as a life-support system in patients with
acute kidney failure. It remains the standard treatment today. The artificial kidney has saved innumerable lives by
making the mortality rate for acute, reversible kidney failure plummet.
Kolff’s triumph with the artificial kidney was only the first step in a career that brims with fresh vision and daring
inventions. He sparked the establishment of the American Society for Artificial Internal Organs, an organization
that has roused tremendous research activity in the field. While improving the original kidney, Kolff branched out
to tackle an array of other artificial organs. He headed a team that invented the first artificial heart, showed that it
worked in animals, and adapted it for human use. In 1982, this device allowed Barney Clark to live for 112 days.
Kolff also designed the intra-aortic balloon pump, a gadget that reduces the heart’s workload and improves blood
flow to the coronary arteries. Surgeons use this apparatus to support the heart when it fails or during particular
medical procedures. Currently in his 90s, Kolff continues to develop artificial organs.
Kolff’s hemodialysis apparatus and its descendents could preserve the life of patients with temporary kidney
failure until their own kidneys began to operate again. But a single patient could benefit from the regimen only a
few times; surgeons inserted tubes that connected a patient’s artery and vein to the artificial kidney, and removed
them after dialysis. With repetition, this procedure thrashed the blood vessels and doctors eventually ran out of
places to tap into the bloodstream. This limitation rendered hemodialysis essentially useless for the tremendous
numbers of people with ESRD, who have permanently ravished kidneys and would require frequent treatment.
TEFLON TECHNIQUE STICKS
Scribner’s invention enlarged the province of hemodialysis to include ESRD patients. As a faculty member at
the University of Washington, Seattle, Scribner encountered a gravely ill patient, whom the medical team had
revived with an artificial kidney. The patient responded unusually well, and within three days, he was wandering
the hospital corridors. But the cure was temporary because it turned out that he had permanent kidney damage.
Despite the amazing recovery, he died soon afterward.
Several weeks later, Scribner woke up in the middle of the night with an idea about how to save such patients.
A U-shaped shunt with one end inserted into an artery and one into a vein could remain attached permanently,
For each round of dialysis, medical personnel could plug tubes into this gadget and hook them up to the artificial
kidney. Blood would flow from the artery to the dialysis machine and then back to the vein. After dialysis concluded,
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the apparatus would be capped, which would reconnect the artery and the vein. In principle, such a piece of
equipment would facilitate repeated rounds of hemodialysis.
Scribner and his associate, surgeon David Dillard, contacted engineer Wayne Quinton. Quinton soon mastered
the art of bending Teflon, a process similar to glass blowing. Teflon was crucial to the device because it repels
virtually all substances; before a blood clot can build up, it slips off. In addition, the material doesn’t react with
tissues and can be shaped. By March of 1960, the three men were ready. They implanted the first shunt into Clyde
Shields, a 39-year-old machinist who was dying of incurable kidney disease. Although kidney experts doubted that
long-term dialysis would succeed because the kidney performs many functions in addition to clearing the blood of
toxic metabolites, Shields would live for 11 years on intermittent hemodialysis and the same therapy would sustain
Scribner’s fifth patient, Tim Albers, for 36 years. Scribner had performed a monumental feat, providing continuous
replacement of an organ’s vital functions in such a way that a patient could survive with a reasonable quality of life.
Suddenly the prognosis for ESRD patients flipped from 90 percent fatal to 90 percent survivable. Scribner
transformed the outlook of patients whose kidneys had failed from almost certain death to a reasonably vigorous
life. Furthermore, the advance opened up the field of kidney transplantation. With the Scribner shunt, potential
recipients could be sustained while they awaited donor organs.
Scribner set up the first outpatient dialysis center in the world, now called the Northwest Kidney Center, but at
first, it could handle only a fraction of patient applicants. Suddenly the world of medicine confronted a perplexing
question: Who should live and who should die? The first bioethics committee consisting of lay people as well as
physicians formed to select the lucky individuals. Many of today’s bioethics discussions owe their origins to the
development of hemodialysis technology that could serve a large number of people in principle, but not in practice.
Scribner played a central role in creating this ethical dilemma, but he quickly found ways to resolve it at least
with regard to hemodialysis. He and his colleagues developed a small, portable device for use in the home, and
included features that allowed non-medically trained personnel to operate it safely. This innovation liberated beds
in the center and also helped patients incorporate the procedure easily into their normal lives.
THE LEGACY
Many investigators, including Kolff and Scribner, have improved their initial designs and approaches. The Scribner
shunt, for example, has been replaced by other gadgets that allow permanent access to blood vessels. Kolff’s and
Scribner’s inventions and ideas, however, represent the pioneering breakthroughs that led to these later developments
and all subsequent techniques have relied upon their original concepts and technology.
Furthermore, the effects of Kolff and Scribner’s advances have reverberated beyond the area of hemodialysis.
The ability to remove toxins from the blood raised the possibility of replacing all kidney functions and galvanized
research efforts aimed at devising ways to therapeutically simulate the rest of this organ’s roles. Such activities
include converting vitamin D to its active form, which is required to build bone; producing erythropoietin, which
stimulates production of red blood cells; and generating hormones that regulate blood pressure. As a result of this
research, physicians have refined their ability to therapeutically substitute for kidney functions; for example, they
now administer recombinant erythropoietin to correct the anemia that almost universally accompanies chronic
kidney failure. Furthermore, the flourishing field of transplantation has brokered new insights into the immune
system’s ability to distinguish self from non-self, and its response to foreign tissue.
For more than half a century, hemodialysis has been saving patients whose kidneys have failed. It has already
touched millions of people, and that number grows every year. The hemodialyzer continues to provide the only
effective therapy for this condition, which stemmed largely from the frustration, imagination, and persistence of
two exceptionally creative medical scientists.
